Patent · US Active

Substituted pyridine-piperazinyl analogues as RSV antiviral compounds

US10150761B2 · kind B2 · utility

0Cited by

1References

10Claims

0Family size

Assignee

Janssen Sciences Ireland UC · IE

Inventors

Jérôme Emile Georges Guillemont · Andé, FR
David Francis Alain Lançois · Louviers, FR
Magali Madeleine Simone Motte · Louviers, FR
Delphine Yvonne Raymonde Lardeau · Issy-les-Moulineaux, FR
Xavier Marc Bourdrez · Louviers, FR
Wendy Mia Albert Balemans · Kalmthout, BE
Dirk André Emmy Roymans · Turnhout, BE

Key dates

Filing date	Jun 23, 2017
Grant date	Dec 11, 2018
Priority date	—
Expiry date	Jun 23, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention concerns novel substituted pyridine-piperazinyl analogs of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.